Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000929638-26-000098
Filing Date
2026-01-09
Accepted
2026-01-09 08:59:56
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8125
2 JOINT FILING AGREEMENT exhibit99-1.htm EX-99.1 4047
  Complete submission text file 0000929638-26-000098.txt   14005
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Subject) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89137 | Film No.: 26521446
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2705, 27/F, CHINA RESOURCES BLDG 26 HARBOUR RD WAN CHAI Hong Kong 999077
Business Address 2705, 27/F, CHINA RESOURCES BLDG 26 HARBOUR RD WAN CHAI Hong Kong 999077 86-18221753137
Bonita Biotech (HK) Ltd (Filed by) CIK: 0002099513 (see all company filings)

EIN.: 000000000 | State of Incorp.: K3 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A